Oncology Clinical Trial
— STEPPOfficial title:
The STEPP Study: Sensors To Evaluate Physical Performance
Verified date | October 2022 |
Source | UNC Lineberger Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study assesses the association between digital functional measures of physical and patient-reported standard onocological assessments, like Karnofsky Performance Score (KPS).
Status | Completed |
Enrollment | 63 |
Est. completion date | August 30, 2022 |
Est. primary completion date | August 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: 1. All genders aged = 18 years of age 2. Patients being seen at UNCCH for treatment of cancer. 3. English-speakers 4. Able to understand and cooperate with study procedures. 5. Patients with solid tumors or hematological malignancies, and self-reported KPS =70 to = 100. Signed and dated informed consent and HIPPA. Exclusion Criteria: 1. Subjects using investigational/experimental products. 2. Has dementia, altered mental status, or any psychiatric or co-morbid condition prohibiting the understanding or rending of informed consent. 3. Unable or unwilling to complete physical performance assessments including the at-home wearable device for 14 days. 4. Unable to speak English. 5. Subjects who report any other medical condition, recreational substance use, or medication use which would prevent them from completing study tasks or impair the providing of informed consent. 6. Subjects who are allergic to silicone or adhesives. Subjects with cardiac pacemakers, electronic pumps or any other implanted medical devices. |
Country | Name | City | State |
---|---|---|---|
United States | UNC Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina |
Lead Sponsor | Collaborator |
---|---|
UNC Lineberger Comprehensive Cancer Center | Pfizer |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Amount of mean steps per day recorded at home | At-home record of mean steps per day | 18 months | |
Primary | Amount of mean sedentary activity time recorded at home | At-home record of minutes per day of mean sedentary activity time | 18 months | |
Primary | Amount of Light activity time recorded at home | At-home record of minutes per day of light activity time per day | 18 months | |
Primary | Amount of moderate activity time recorded at home | At-home record of minutes per day of moderate activity time | 18 months | |
Primary | Amount of vigorous activity time recorded at home | At-home record of minutes per day of vigorous activity time | 18 months | |
Primary | Self-Reported Karnofsky Performance Score (KPS) | The validated 1 question Self-reported Karnofsky Performance Score (KPS) score 0 to 100 will be measured. Scores closer to 100 indicate high performance of the patient | 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01439152 -
Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Active, not recruiting |
NCT06015009 -
Symptom Management App for Children at the Early Stage of Cancer Survivorship and Their Caregivers
|
N/A | |
Active, not recruiting |
NCT03298100 -
Risk Scoring Model for Endometrial Cancer
|
||
Recruiting |
NCT05055609 -
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT04324320 -
Psychological Distress in Outpatient Oncological Rehabilitation
|
||
Completed |
NCT00588289 -
Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA
|
N/A | |
Recruiting |
NCT06222801 -
The 1st Tumor CytokinoTherapy Database (TCTD-1)
|
||
Recruiting |
NCT03831633 -
Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients
|
Phase 4 | |
Completed |
NCT04914702 -
Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
|
||
Recruiting |
NCT05198570 -
Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
|
||
Recruiting |
NCT05712174 -
A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT03832062 -
Value of Analysing Under-utilised Leftover Tissue (VauLT)
|
||
Completed |
NCT03988777 -
Magnetic Seed Localisation for Nonpalpable Breast Lesions
|
||
Recruiting |
NCT06031233 -
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
|
Phase 4 | |
Enrolling by invitation |
NCT04019119 -
Digital Intervention for the Modification of Lifestyles (iGame)
|
N/A | |
Not yet recruiting |
NCT05926362 -
Capillary-Venous Paired Data Collection
|
||
Recruiting |
NCT05686213 -
ExeNTrO: Exercise During Neoadjuvant Chemoradiation Treatment to Improve Rectal and Esophageal Cancer Outcome - Pilot Trial
|
Phase 2 | |
Recruiting |
NCT05510856 -
Comparative Clinical Study Evaluating the Possible Efficacy of Duloxetine, Gabapentin and Lacosamide on Oxaliplatin-Induced Peripheral Neuropathy in Cancer Patients
|
Phase 4 | |
Completed |
NCT04933604 -
LPN in Patients With High-complex Renal Tumors
|